Novo Nordisk postpones Wegovy label expansion

Novo Nordisk has withdrawn its application to expand the usage of Wegovy, its weight loss drug. The decision, based on interactions with the FDA, comes despite positive trial results for adults with obesity and heart failure. The firm aims to resubmit the application in early 2025 with additional data from a kidney outcomes trial.